Table 3.
Treatment of recurrence for patients after liver metastases resection
| Characteristics | Before PSM (n = 240) | After PSM (n = 99) | ||||
|---|---|---|---|---|---|---|
| Right-sided group (n = 54) | Left-sided group (n = 186) | P value | Right-sided group (n = 53) | Left-sided group (n = 46) | P value | |
| Resection alone, n (%) | 3 (5.6) | 20 (10.7) | 0.306 | 3 (5.7) | 9 (19.6) | 0.134 |
| Ablation alone, n (%) | 11 (20.4) | 29 (15.6) | 0.407 | 11 (20.8) | 7 (15.2) | 0.476 |
| Chemotherapy alone, n (%) | 27 (50.0) | 70 (37.7) | 0.103 | 18 (34.0) | 17 (37.0) | 0.756 |
| Resection + chemotherapy, n (%) | 3 (5.6) | 9 (4.8) | 0.735 | 3 (5.7) | 2 (4.3) | 1.000 |
| Resection + radiotherapy, n (%) | 1 (1.8) | 3 (1.6) | 0.905 | 1 (1.8) | 0 (0.0) | NA |
| Ablation + chemotherapy, n (%) | 3 (5.6) | 25 (13.4) | 0.149 | 3 (5.7) | 2 (4.3) | 1.000 |
| Ablation + radiotherapy, n (%) | 0 (0.0) | 2 (1.1) | NA | 0 (0.0) | 0 (0.0) | NA |
| Radio + chemotherapy, n (%) | 0 (0.0) | 2 (1.1) | NA | 0 (0.0) | 0 (0.0) | NA |
| Supportive care, n (%) | 6 (11.1) | 26 (14.0) | 0.585 | 14 (26.4) | 9 (19.6) | 0.421 |
PSM propensity score matching